Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune tolerance induction with turoctocog alfa after inhibitor development on turoctocog alfa pegol
2016-003821-40Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of turoctocog alfa in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Number of adverse events. Started Dec 2016; status: completed.
02
Drugs
turoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2016-003821-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003821-40.